Perioperative management of antiphospholipid antibody positive patients during noncardiac surgeries

Perioperative Management of Patients with Rheumatic Disease

Volumn , Issue , 2013, Pages 91-107

  Saunders, Katherine H ^a   Erkan, Doruk ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Barbara Volcker Center for Women and Rheumatic Disease Hospital for Special Surgery Cornell University ^*  (United States)

Author keywords

Anticoagulation; Antiphospholipid antibodies; Antiphospholipid syndrome; Thrombosis

Indexed keywords

EID: 84901327692     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-2203-7_8     Document Type: Chapter

References (96)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classi fication criteria for de finite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
2. Asherson RA, Cervera R, de Groot PG, et al; for the Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classi fication criteria and treatment guidelines. Lupus. 2003;12:530-4.
3. Vila P, Hernández MC, López-Fernández MF, Batlle J. Prevalence, follow-up and clinical signi ficance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994;72:209-13.
4. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism - results of the Spanish Multicentric Study on Thrombophilia (EMET-study). Thromb Haemost. 1997;77:444-51.
5. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15:145-51.
6. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050-7.
7. Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril. 1996; 66:24-9.
8. Erkan D, Lockshin M. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2009;5:160-70.
9. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106:2340-6.
10. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thromb Haemost. 1997;78:1-6.
11. Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classi fication criteria. Ann Rheum Dis. 2007;66:927-30.
12. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41:924-9.
13. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001;80:355-76.
14. Erkan D, Lockshin MD. What is antiphospholipid syndrome? Curr Rheumatol Rep. 2004;6:451-7.
15. Asherson RA, Chan JK, Harris EN, Gharavi AE, Hughes GR. Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal. Ann Rheum Dis. 1985;44:823-5.
16. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants - a prospective study. Thromb Haemost. 1994;72:222-6.
17. Yamamoto T, Ito M, Nagata S, et al. Catastrophic exacerbation of antiphospholipid syndrome after lung adenocarcinoma biopsy. J Rheumatol. 2000; 27:2035-7.
18. Erkan D, Bateman H, Lockshin MD. Lupus anticoagulant- hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus. 1999;8:560-4.
19. Erkan D, Leibowitz E, Berman J, Lockshin MD. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29:843-9.
20. Chouhan VD, Comerota AJ, Sun L, Harada R, Gaughan JP, Rao AK. Inhibition of tissue factor pathway during intermittent pneumatic compression: a possible mechanism for antithrombotic effect. Arterioscler Thromb Vasc Biol. 1999;19:2812-7.
21. Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby GP, Reddy DJ. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev. 2008;4:CD005258.
22. Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep. 2007;9: 212-8.
23. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-32.
24. Pengo V, Biasiolo A, Gresele P, et al; for the Participating Centres of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007;5:925-30.
25. Pengo V, Tripodi A, Reber G, et al; for the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scienti fic and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7:1737-40.
26. Trappe R, Loew A, Thuss-Patience P, Dörken B, Riess H. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol. 2006;85:134-5.
27. Cuadrado MJ, Mujic F, Muñoz E, Khamashta MA, Hughes GR. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis. 1997;56:194-6.
28. Tenidios F, Erkan D, Lockhsin MD. Rituximab in primary antiphospholipid syndrome (abstract). Arthritis Rheum. 2005;52:4078.
29. Shaulian E, Shoenfeld Y, Berliner S, Shaklai M, Pinkhas J. Surgery in patients with circulating lupus anticoagulant. Int Surg. 1981;66:157-9.
30. Vinet E, Rich E, Senécal JL. Thromboembolism complicating the treatment of lupus anticoagulant hypoprothrombinemia syndrome. J Rheumatol. 2006;33: 2088-90.
31. Simel D, St. Claire EW, Adams J, Greenberg C. Correction of hypothrombinemia by immunosuppressive treatment of lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med. 1987;83:563-6.
32. Ra flores MB, Kaplan RB, Spero JA. Pre-operative management of a patient with hypoprothrombinemialupus anticoagulant syndrome. Thromb Haemost. 2007;98:248-50.
33. Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome. Br J Haematol. 1996;93:1-5.
34. Sevitt S. Pathology and pathogenesis of deep vein thrombosis. In: Bergan J, Yao J, editors. Venous problems. Chicago: Year Book; 1976. p. 257-69.
35. Kraai EP, Lopes RD, Alexander JH, Garcia D. Perioperative management of anticoagulation: guidelines translated for the clinician. J Thromb Thrombolysis. 2009;28:16-22.
36. Geerts WH, Bergqvist D, Pineo GF, et al; for the American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133:381S-453S.
37. Lumpkin MM. FDA public health advisory. Anesthesiology. 1998;88:27A-8.
38. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Anesth Analg. 1997;85:874-5.
39. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidencebased guidelines (3rd ed). Reg Anesth Pain Med. 2010;35:64-101.
40. Douketis JD, Berger PB, Dunn AS, et al; for the American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians evidencebased clinical practice guidelines (8th ed). Chest. 2008;133:299S-339S.
41. McBane RD, Wysokinski WE, Daniels PR, et al. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30:442-8.
42. O'Donnell MJ, Kearon C, Johnson J, et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med. 2007;146:184-7.
43. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost. 2005; 94:528-31.
44. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119:132S-75.
45. Madan R, Khoursheed M, Kukla R, al-Mazidi M, Behbehani A. The anaesthetist and the antiphospholipid syndrome. Anaesthesia. 1997;52:72-6.
46. Faltas B, Kouides PA. Update on perioperative bridging in patients on chronic oral anticoagulation. Expert Rev Cardiovasc Ther. 2009;7:1533-9.
47. Kasthuri RS, Roubey RA. Warfarin and the antiphospholipid syndrome. Does one size fit all? Arthritis Rheum. 2007;57:1346-7.
48. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology. 2008;109:918-26.
49. Vigué B. Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care. 2009;13:209.
50. Bernstein ML, Salusinsky-Sternbach M, Belle fleur M, Esseltine DW. Thrombotic and hemorrhagic complications in children with the lupus anticoagulant. Am J Dis Child. 1984;138:1132-5.
51. Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg. 1978;49:378-81.
52. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med. 2000;160:2327-32.
53. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 1998;339:80-5.
54. Cheng JS, Arnold PM, Anderson PA, Fischer D, Dettori JR. Anticoagulation risk in spine surgery. Spine (Phila Pa 1976). 2010;35:S117-24.
55. Roth J, Margalit NS, Kesler A, Korn A, Ram Z. Perioperative brainstem infarct in a patient with antiphospholipid antibody (APLA) syndrome. Acta Neurochir (Wien). 2006;148:1111-5.
56. Cherian J, Gertner E. Recurrent pulmonary embolism despite inferior vena cava filter placement in patients with the antiphospholipid syndrome. J Clin Rheumatol. 2005;11:56-8.
57. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338:409-15.
58. Zifman E, Rotman-Pikielny P, Berlin T, Levy Y. Insertion of inferior vena cava filters in patients with the antiphospholipid syndrome. Semin Arthritis Rheum. 2009;38:472-7.
59. Ebato M, Kitai H, Kumakura H, Nakamura Y, Shimizu N, Takeyama Y. Thrombus on the tricuspid valve in a patient with primary antiphospholipid syndrome after implantation of an inferior vena cava filter. Circ J. 2002;66:425-7.
60. Vaidya S, Sellers R, Kimball P, et al. Frequency, potential risk and therapeutic intervention in endstage renal disease patients with antiphospholipid antibody syndrome: a multicenter study. Transplantation. 2000;69:1348-52.
61. Vaidya S, Gugliuzza K, Daller JA. Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome. Transplantation. 2004;77:1046-9.
62. Stone JH, Amend WJ, Criswell LA. Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis. 1999;34:1040-7.
63. McIntyre JA, Wagenknecht DR. Antiphospholipid antibodies. Risk assessments for solid organ, bone marrow, and tissue transplantation. Rheum Dis Clin North Am. 2001;27:611-31.
64. Raklyar I, DeMarco J, Wu J, Light J, Timbil S, Weinstein A. Anticardiolipin antibody positivity correlates with poor graft survival in renal transplantation for systemic lupus erythematosus (abstract). Arthritis Rheum. 2005;52:S384-5.
65. Wagenknecht DR, Becker DG, LeFor WM, McIntyre JA. Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation. 1999;68: 241-6.
66. Forman JP, Lin J, Pascual M, Denton MD, Tolkoff- Rubin N. Signi ficance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant. 2004;4:1786-91.
67. Ruffatti A, Marson P, Valente M, et al. Plasma exchange in a patient with primary antiphospholipid syndrome undergoing kidney transplantation. Transpl Int. 2007;20:475-7.
68. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887-95.
69. Silverberg M, Erkan D, Lockshin MD. Hemorrhage in the antiphospholipid syndrome: the challenge of anticoagulation. Arthritis Rheum. 2002;46:S52.
70. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6:98-103.
71. Deane KD, West SG. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum. 2005;35:154-65.
72. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J. 1974;1:436-40.
73. Llau JV, Lopez-Forte C, Sapena L, Ferrandis R. Perioperative management of antiplatelet agents in noncardiac surgery. Eur J Anaesthesiol. 2009;26:181-7.
74. Samama CM, Bastien O, Forestier F, et al; for the French Society of Anesthesiology and Intensive Care. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001-summary statement. Can J Anaesth. 2002;49:S26-35.
75. O'Riordan JM, Margey RJ, Blake G, O'Connell PR. Antiplatelet agents in the perioperative period. Arch Surg. 2009;144:69-76.
76. Jancinová V, Nosál R, Petríková M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res. 1994;74:495-504.
77. Lombard-Platlet S, Bertolino P, Deng H, Gerlier D, Rabourdin-Combe C. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell. Immunology. 1993;80:566-73.
78. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000;95:3460-6.
79. Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res. 2004;114:467-76.
80. Pierangeli SS, Vega-Ostertag ME, González EB. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med. 2007;9:1-15.
81. Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112:1687-95.
82. Johnson R, Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res. 1979;144: 174-7.
83. Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 1987;30:1435-6.
84. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5:S16-22.
85. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009;68:238-41.
86. Ho KT, Ahn CW, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford). 2005;44:1303-7.
87. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487-95.
88. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and in flammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 2003;48:3272-9.
89. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2- glycoprotein I) antibodies: effect on the proadhesive and proin flammatory phenotype. Arthritis Rheum. 2001;44:2870-8.
90. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells (abstract). J Thromb Haemost. 2004;2:1558-63.
91. Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost. 2002;88:41-7.
92. Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373: 1175-82.
93. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851-61.
94. Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006;105:1260-72.
95. Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg. 2007;104:1326-33.
96. Fleisher LA, Beckman JA, Brown KA, et al. ACC/ AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 2002 guidelines on perioperative cardiovascular evaluation for noncardiac surgery). Anesth Analg. 2008;106:685-712.